摘要
曲妥珠单抗是人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)的特异性拮抗剂,是治疗乳腺癌的第一个分子靶向药物,自1998年上市以来,已有20余年的临床应用史。但随着应用时间的延长,其引发的不良反应报道也越来越多。通过查阅文献,就曲妥珠单抗相关不良反应的类型、监测及防治手段进行了综述,为临床合理用药提供参考。
Trastuzumab is a specific antagonist of human epidermal growth factor receptor-2(HER-2).It is the first molecular-targeted drug for the treatment of breast cancer.Since its market debut in 1998,trastuzumab has been in clinical application for more than 20 years.However,with the extension of clinical application,more and more adverse reactions are reported.By consulting the literature,the types,monitoring and prevention of trastuzumab related adverse reactions were reviewed in this paper so as to provide reference for clinical rational drug use.
作者
毕亮亮
韩若凌
焦子义
BI Liangliang;HAN Ruoling;JIAO Ziyi(The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China;Affiliated Hospital of Hebei University, Baoding 071000, China)
出处
《医学研究与教育》
CAS
2020年第3期32-38,共7页
Medical Research and Education
基金
河北省科学技术研究与发展计划项目(19277761D)
河北省医学科学研究重点课题计划项目(20180725)。
关键词
曲妥珠单抗
不良反应
心脏毒性
监测
防治
trastuzumab
adverse reactions
cardiotoxicity
monitoring
prevention
